Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

Executive Summary

• Helix BioPharma Corp. and metaShape Pharma AG have extended their exclusive Research and Option Agreement for the LEUMUNA™ program through December 31, 2028.
• The extension preserves Helix’s optionality to commercialize LEUMUNA™ in high‑value metabolic indications while allowing continued pre‑clinical research on MS 001 (ulodesine hemiglutarate).
• The agreement underscores Helix’s strategy to leverage non‑oncology assets for additional value creation beyond its core oncology pipeline.

Key Details

• Agreement Extension: Original April 2023 Agreement now extended to 31 Dec 2028, adding runway for research and option exercise.
• Program Focus: LEUMUNA™ (oral immune checkpoint modulator) and metaShape’s MS 001 co‑therapy aimed at enhancing adipose‑tissue selectivity and durability of weight loss when combined with GLP‑1 agonists (e.g., semaglutide).
• Pre‑clinical Data Highlights (metaShape):
• ↑ Inosine & NAD⁺ levels → improved mitochondrial function.
• Enhanced energy expenditure in adipose tissue.
• Mice on obesogenic diet showed greater weight loss and reduced regain after GLP‑1 withdrawal.
• Strategic Rationale (Helix): Extension maintains long‑term optionality in metabolic indications while keeping primary focus on oncology assets.
• Leadership Comments:
• Randall Riggs, CEO of metaShape – emphasizes progress and upcoming updates on MS 001.
• Thomas Mehrling, MD, PhD, CEO of Helix – cites quality of emerging pre‑clinical data and potential cross‑indication benefits.
• Corporate Context: Helix acquired Laevoroc Immunology AG’s assets (including rights to LEUMUNA™) in Nov 2024; this extension follows that acquisition.

Notable Quotes

“The extension of this agreement aligns with a period of meaningful progress for metaShape,” – Randall Riggs, CEO, metaShape Pharma.

“From Helix’s perspective, the decision to extend this agreement is grounded in the quality of the emerging preclinical data around MS 001… This program also reinforces the breadth of Helix’s science and its ability to generate value beyond oncology.” – Thomas Mehrling, MD, PhD, CEO, Helix BioPharma.